<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><generator><![CDATA[NewsEdge RSS Feeder]]></generator><title><![CDATA[Latest News on Janssen-Cilag.com]]></title><link><![CDATA[http://www.janssen-cilag.com/]]></link><description><![CDATA[Latest News on Janssen-Cilag.com]]></description><language>en-us</language><managingEditor><![CDATA[info@janssen-cilag.com]]></managingEditor><webMaster><![CDATA[webmaster@janssen-cilag.com]]></webMaster><copyright><![CDATA[Janssen-Cilag 2005 - Copyright]]></copyright><image><title><![CDATA[NewsEdge RSS Feeder]]></title><link><![CDATA[http://www.janssen-cilag.com/]]></link><url><![CDATA[/content/images/janssen-cilag.emea_com/top/logo.gif]]></url><width>199</width><height>39</height></image><item><title><![CDATA[STELARA(tm) shows greater efficacy than etanercept for treatment of moderate to severe plaque psoriasis]]></title><pubDate>Thu, 14 Jan 2010 00:00:00 -0500</pubDate><description><![CDATA[Results from first Phase III comparator study of biologic agents in psoriasis published today in New England Journal of Medicine]]></description><link><![CDATA[http://www.janssen-cilag.com/news/detail.jhtml?itemname=stelara_efficacy&action=view]]></link><author>info@janssen-cilag.com</author><category>News/All News</category></item><item><title><![CDATA[Metabolic effects significantly lower with INVEGA® compared to oral olanzapine in people with schizophrenia]]></title><pubDate>Wed, 18 Nov 2009 00:00:00 -0500</pubDate><description><![CDATA[New data from a 6-month open label randomised controlled trial show INVEGA® (paliperidone ER) is associated with significantly less metabolic effects compared to oral olanzapine in people with schizophrenia, while demonstrating comparable efficacy.]]></description><link><![CDATA[http://www.janssen-cilag.com/news/detail.jhtml?itemname=metaboliceffectsinvega&action=view]]></link><author>info@janssen-cilag.com</author><category>News/All News</category></item><item><title><![CDATA[Priligy first oral prescription medication approved for PE]]></title><pubDate>Tue, 10 Feb 2009 00:00:00 -0500</pubDate><description><![CDATA[Priligy™ (dapoxetine) receives first regulatory approvals for the treatment of premature ejaculation (PE) in Finland and Sweden]]></description><link><![CDATA[http://www.janssen-cilag.com/news/detail.jhtml?itemname=priligy&action=view]]></link><author>info@janssen-cilag.com</author><category>News/All News</category></item><item><title><![CDATA[New Antibiotic To Treat Serious Infections]]></title><pubDate>Fri, 30 May 2008 00:00:00 -0400</pubDate><description><![CDATA[European Authority Recommends Approval of DORIBAX for treatment of nosocomial pneumonia, complicated intra-abdominal and complicated urinary tract infections]]></description><link><![CDATA[http://www.janssen-cilag.com/news/detail.jhtml?itemname=new_antibiotic&action=view]]></link><author>info@janssen-cilag.com</author><category>News/All News</category></item><item><title><![CDATA[Invega® receives marketing authorisation in European Union for threatment of schizophrenia.]]></title><pubDate>Thu, 28 Jun 2007 00:00:00 -0400</pubDate><description><![CDATA[Invega® receives marketing authorisation in European Union for threatment of schizophrenia. First Oral Prolonged-Release Medication to Treat Schizophrenia.]]></description><link><![CDATA[http://www.janssen-cilag.com/news/detail.jhtml?itemname=invega_approval_eu&action=view]]></link><author>info@janssen-cilag.com</author><category>News/All News</category></item><item><title><![CDATA[Janssen-Cilag International NV submits marketing authorization application in Europe for new antiobiotic.]]></title><pubDate>Mon, 18 Jun 2007 00:00:00 -0400</pubDate><description><![CDATA[Janssen-Cilag International NV submits marketing authorization application in Europe for new antiobiotic ceftobiprole, an investigational antibiotic for the treatment of complicated skin and soft tissue infections (cSSTI) including diabetic foot infections.]]></description><link><![CDATA[http://www.janssen-cilag.com/news/detail.jhtml?itemname=ceftobiprole_authorisation&action=view]]></link><author>info@janssen-cilag.com</author><category>News/All News</category></item><item><title><![CDATA[INVEGA® receives positive opinion from European Committee for Human Medicinal Products (CHMP)]]></title><pubDate>Wed, 02 May 2007 00:00:00 -0400</pubDate><description><![CDATA[ INVEGA® receives positive opinion from European Committee for Human Medicinal Products for Treatment of Schizophrenia.]]></description><link><![CDATA[http://www.janssen-cilag.com/news/detail.jhtml?itemname=invega_CHMP&action=view]]></link><author>info@janssen-cilag.com</author><category>News/All News</category></item><item><title><![CDATA[INVEGA™ approved by FDA as new treatment for schizophrenia]]></title><pubDate>Wed, 20 Dec 2006 00:00:00 -0500</pubDate><description><![CDATA[ The U.S. Food and Drug Administration (FDA) has approved INVEGA™ (paliperidone) Extended-Release Tablets, a new atypical antipsychotic, for the treatment of schizophrenia. ]]></description><link><![CDATA[http://www.janssen-cilag.com/news/detail.jhtml?itemname=invega&action=view]]></link><author>info@janssen-cilag.com</author><category>News/All News</category></item><item><title><![CDATA[Mother & daughters' journey through madness]]></title><pubDate>Mon, 11 Dec 2006 00:00:00 -0500</pubDate><description><![CDATA[ Out of the Shadow, Susan Smiley's award-winning documentary film, is now available to view on our European Psychiatry 24x7 website www.psychiatry24X7.com.]]></description><link><![CDATA[http://www.janssen-cilag.com/news/detail.jhtml?itemname=news_outoftheshadow&action=view]]></link><author>info@janssen-cilag.com</author><category>News/All News</category></item><item><title><![CDATA[European Headache Alliance launches at European Parliament with 1st ever Migraine Day of Action]]></title><pubDate>Wed, 20 Sep 2006 00:00:00 -0400</pubDate><description><![CDATA[Migraine patients unite to end intolerance and prejudice against people living with migraine ]]></description><link><![CDATA[http://www.janssen-cilag.com/news/detail.jhtml?itemname=Migraine&action=view]]></link><author>info@janssen-cilag.com</author><category>News/All News</category></item></channel></rss>

